Is the combination of Lazertinib and Amivantamab effective in treating lung cancer?

The combination therapy of lazertinib and evantumumab showed superior efficacy in the latest phase III clinical study of MARIPOSA, especially in patients with non-small cell lung cancer (NSCLC) with EGFR gene mutations. Research data shows that the median progression-free survival (PFS) of patients treated with combination therapy reaches 23.7 months, which is significantly better than the currently widely used Osimertinib (Osimertinib) monotherapy group's 16.6 months. This shows that combined treatment can effectively delay disease progression and bring patients a longer remission period and treatment window.

For lung cancer patients with brain metastases, controlling central nervous system (CNS) lesions is always difficult to treat. Combination therapy also shows advantages in this regard. After excluding patients with brain-only progression, the median PFS was extended to 27.5 months, which was better than osimertinib's 18.4 months. This shows that lazertinib's good central nervous system penetration ability synergizes with amivantamab to have a more lasting control effect on brain metastases and provide new treatment opportunities for patients with CNS lesions.

Although combined use may lead to more adverse reactions, the overall safety is still acceptable. Common adverse events included rash, paronychia, and infusion-related reactions, most of which were grade 1–2. The incidence rate of grade 3 or above adverse reactions such as rash and thrombosis is about 10%, but most of them can be controlled through treatment adjustment and supportive care. Compared with osimertinib, although it has slightly more side effects, it is generally well tolerated by patients and has a low discontinuation rate, indicating its strong clinical sustainability.

In 2024, this combination regimen has been approved by the U.S. FDA for the first-line treatment of EGFR mutated NSCLC. The European Medicines Agency also gave a positive review and recommended approval for marketing. This combination therapy targeting the dual mechanisms of EGFR and MET provides new ideas for overcoming single-drug resistance and prolonging efficacy. In the future, as the data further matures, this combination therapy is expected to gradually replace osimertinib and become EGFRThe preferred first-line drug regimen for patients with mutant non-small cell lung cancer.

Reference materials:https://www.drugs.com/donanemab.html